2019
DOI: 10.1159/000497430
|View full text |Cite
|
Sign up to set email alerts
|

C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges

Abstract: Diffuse large B cell lymphoma (DLBCL), an aggressive cancer of the B cells, is the most common subtype of non-Hodgkin lymphoma (NHL) worldwide. In China, the cases of DLBCL increase yearly. C-X-C chemokine receptor 4 (CXCR4) has been implicated in the migration and trafficking of malignant B cells in several hematological malignancies, and only a few reports have been published on the role of CXCR4 in the metastasis of DLBCL. This review summarizes the relevant perspectives on the functional mechanism, prognos… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
16
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 17 publications
(19 citation statements)
references
References 83 publications
3
16
0
Order By: Relevance
“…Survival analysis revealed a trend for high CXCR4 expression associated with poor survival, in concordance with the findings of two other research groups [13,14,20]. Together with the fact that CXCR4-CXCL12 signaling activates several pathways like Janus kinases-signal transducer and activator of transcription (JAK-STAT), phosphoinositide 3-kinase (PI3K), protein kinase B (PKB, AKT), mitogen-activated protein kinase (MAPK), and NF-κB [43,44,45], we hypothesize that the high co-occurrence of the receptor and its ligand influences the resistance of lymphomas toward anti-lymphoma therapy. Hence, we expect that low or even no CXCR4 expression leads to none or low activation of the mentioned pathways, thus leading to a higher therapeutic sensitivity of the lymphoma cells.…”
Section: Discussionsupporting
confidence: 84%
“…Survival analysis revealed a trend for high CXCR4 expression associated with poor survival, in concordance with the findings of two other research groups [13,14,20]. Together with the fact that CXCR4-CXCL12 signaling activates several pathways like Janus kinases-signal transducer and activator of transcription (JAK-STAT), phosphoinositide 3-kinase (PI3K), protein kinase B (PKB, AKT), mitogen-activated protein kinase (MAPK), and NF-κB [43,44,45], we hypothesize that the high co-occurrence of the receptor and its ligand influences the resistance of lymphomas toward anti-lymphoma therapy. Hence, we expect that low or even no CXCR4 expression leads to none or low activation of the mentioned pathways, thus leading to a higher therapeutic sensitivity of the lymphoma cells.…”
Section: Discussionsupporting
confidence: 84%
“…Consistent with this, in recent years genomic findings have provided important insights into the relevance of the CXCL12/CXCR4 axis for pathogenesis, prognostication, and treatment outcome of cancer. As CXCL12 regulates hematopoietic cell trafficking to positioning in the BM [20], it is not surprising that aberrant CXCR4 expression on cancer cells from several hematopoietic malignancies influences neoplasia progression by controlling cancer cell migration to BM as well as to lymph nodes, suggesting CXCR4 as a novel, reliable prognostic biomarker [21]. In particular, somatic CXCR4 mutations have been reported in indolent forms of B-cell nHL, follicular lymphoma, and WM [22,23].…”
Section: Waldenstrom's Macroglobulinaemiamentioning
confidence: 99%
“…CXCL10 also named interferon-γ-inducible protein 10 (IP-10) is identified as a Th1 cell-attracting chemokines that is bound to CXCR3 which is mainly expressed on Th1 cells (24,25) . CCL20 also named liver-and activation-regulated chemokine (LARC) is identified as a Th17 cell-attracting chemokines that is bound to CCR6 which is mainly expressed on Th17 cells (24,25) . The capacity of CagA-positive HP strains to induce higher amounts of CXCL10 and CCL20 indicate that these strains induces higher accumulation FIGURE 8.…”
Section: Discussionmentioning
confidence: 99%